What tests does the doctor usually conduct before taking Platinib (Pujihua) for the first time?

Before a patient starts taking Pralsetinib (Pralsetinib) for the first time, doctors usually conduct a series of systematic and comprehensive examinations to ensure that the patient is suitable for using the drug and to minimize the risk of adverse reactions. These examinations not only help clarify the type and molecular characteristics of the disease, but also provide important basis for subsequent treatment effect evaluation and dose adjustment.

First, doctors will conduct detailed genetic testing, which is a key step in using platinib. Platinib is a selective RET inhibitor, mainly suitable for patients with RET gene fusion-positive non-small cell lung cancer and thyroid cancer. Therefore, before starting treatment, doctors usually test patients for the presence of RET gene mutations or fusions through molecular diagnostic techniques such as NGS (high-throughput sequencing) or PCR. If there are no clear positive results for RET fusion, platinib is generally not recommended to avoid ineffective use.

Secondly, the doctor will arrange routine hematology and biochemical tests, including liver function, kidney function, electrolyte levels, blood routine, etc. These examinations help understand the patient's overall physical condition and organ function, and determine whether intervention or adjustments are needed before treatment. In addition, platinib may have some effects on liver function, blood pressure, and heart, so the initial examination can serve as baseline data to monitor changes during subsequent treatment.

Finally, imaging examinations, such as chest CT, PET-CT or MRI, will also be performed to evaluate the specific location, size and metastasis of the tumor, and to determine the stage of the disease and treatment goals. For patients with thyroid cancer, neck ultrasound and thyroid function tests may also be needed. Based on these examination results, the doctor will formulate an individualized treatment plan for the patient, clarify the dosage and monitoring plan of Platinib, and ensure that treatment is started under the premise of safety and effectiveness.

Reference materials:https://www.drugs.com/